Cargando…
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
Precise biomarkers are needed to guide better diagnostics and therapeutics for basal-like breast cancer, for which DNA-dependent protein kinase catalytic subunit (DNA-PKcs) has been recently reported by the Clinical Proteomic Tumor Analysis Consortium as the most specific biomarker. We evaluated DNA...
Autores principales: | Asleh, Karama, Riaz, Nazia, Cheng, Angela S., Gao, Dongxia, Leung, Samuel C. Y., Anurag, Meenakshi, Nielsen, Torsten O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429676/ https://www.ncbi.nlm.nih.gov/pubmed/34504086 http://dx.doi.org/10.1038/s41523-021-00320-x |
Ejemplares similares
-
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022) -
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
por: Stovgaard, Elisabeth S, et al.
Publicado: (2021) -
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
por: Shenasa, Elahe, et al.
Publicado: (2022) -
Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes
por: Asleh, Karama, et al.
Publicado: (2022) -
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)